Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to upfront and milestone payments, deal also includes effective royalties above 30 percent of annual net sales.
You may also be interested in...
FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
The agency requested the weight loss pill be voluntarily recalled by Eisai, the death knell for a trio of obesity drugs that launched early in the last decade.
FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
The agency requested the weight loss pill be voluntarily recalled by Eisai, the death knell for a trio of obesity drugs that launched early in the last decade.
Arena Says Patient Programs Will Offset Belviq’s Premium Price For Some
The obesity pill will be priced at a slight premium to Vivus’ rival drug Qsymia, but Arena CEO says the amount patients will actually pay will vary based on coupon and rebate programs.